Ordering Recommendation

Molecular testing is preferred for patients presenting with meningitis/encephalitis. Refer to Meningitis/Encephalitis Panel by PCR (2013305).

Mnemonic
ENCEPHCSF
Methodology

Semi-Quantitative Enzyme-Linked Immunosorbent Assay/Semi-Quantitative Chemiluminescent Immunoassay

Performed

Sun-Sat

Reported

4-6 days

New York DOH Approval Status
Specimens from New York clients will be sent out to a New York DOH approved laboratory, if possible.
Specimen Required
Patient Preparation
Collect

CSF.

Specimen Preparation

Transfer 3 mL CSF to an ARUP Standard Transport Tube. (Min: 1.05 mL)

Storage/Transport Temperature

Refrigerated.

Unacceptable Conditions

Serum or plasma. Contaminated, heat-inactivated, or hemolyzed specimens.

Remarks
Stability

Ambient: 8 hours; Refrigerated: 2 weeks; Frozen: 1 year

Reference Interval
Test Number
Components
Reference Interval
0054440 Measles (Rubeola) Antibody, IgG, CSF Effective September 3, 2019
13.4 AU/mL or less Negative - No significant level of IgG antibody to measles (rubeola) virus detected.
13.5-16.4 AU/mL Equivocal - Repeat testing in 10-14 days may be helpful.
16.5 AU/mL or greater Positive - IgG antibody to measles (rubeola) detected, which may indicate a current or past measles (rubeola) infection.

0054441 Measles (Rubeola) Antibody, IgM, CSF
0.79 AU or less Negative - No significant level of IgM antibodies to measles (rubeola) virus detected.
0.80-1.20 AU Equivocal - Repeat testing in 10-14 days may be helpful.
1.21 AU or greater Positive - IgM antibodies to measles (rubeola) virus detected. Suggestive of current or recent infection or immunization.  However, low levels of IgM antibodies may occasionally persist for more than 12 months post-infection or immunization.

0054442 Mumps Virus Antibody IgG, CSF Effective August 20, 2012
8.9 AU/mL or less Negative - No significant level of detectable IgG mumps virus antibody.
9.0-10.9 AU/mL Equivocal - Repeat testing in 10-14 days may be helpful.
11.0 AU/mL or greater Positive - IgG antibody to mumps virus detected, which may indicate a current or past mumps virus infection.

0054443 Mumps Virus Antibody IgM, CSF
0.79 IV or less Negative - No significant level of detectable IgM antibody to Mumps virus.
0.80-1.20 IV Equivocal - Borderline levels of IgM antibody to Mumps virus. Repeat testing in 10-14 days may be helpful.
1.21 IV or greater Positive - Presence of IgM antibody to Mumps virus detected, which may indicate a current or recent infection. However, low levels of IgM antibody may occasionally persist for more than 12 months post-infection or immunization.

0054444 Varicella-Zoster Virus Antibody, IgG, CSF Effective February 18, 2020
134.9 IV or less Negative - No significant level of IgG antibody to varicella-zoster virus detected.
135.0-164.9 IV Equivocal - Repeat testing in 10-14 days may be helpful.
165.0 IV or greater Positive - IgG antibody to varicella-zoster virus detected, which may indicate a current or past varicella-zoster infection.

0054445 Varicella-Zoster Virus Antibody, IgM by ELISA (CSF)
0.90 ISR or less Negative - No significant level of IgM antibody to varicella-zoster virus detected.
0.91-1.09 ISR Equivocal - Repeat testing in 10-14 days may be helpful.
1.10 ISR or greater Positive - Significant level of IgM antibody to varicella-zoster virus detected, which may indicate current or recent infection.  However, low levels of IgM antibodies may occasionally persist for more than 12 months post-infection.

0050408 Herpes Simplex Virus Type 1 and/or 2 Antibodies, IgM by ELISA, CSF
0.89 IV or less Negative - No significant level of detectable HSV IgM antibody.
0.90-1.09 IV Equivocal - Questionable presence of IgM antibodies.  Repeat testing in 10-14 days may be helpful.
1.10 IV or greater Positive - IgM antibody to HSV detected, which may indicate a current or recent infection. However, low levels of IgM antibodies may occasionally persist for more than 12 months post-infection.

0050394 Herpes Simplex Virus Type 1 and/or 2 Antibodies, IgG, CSF
0.89 IV or less Negative - No significant level of detectable HSV IgG antibody.
0.90-1.09 IV Equivocal - Questionable presence of IgG antibodies. Repeat testing in 10-14 days may be helpful.
1.10 IV or greater Positive - IgG antibody to HSV detected which may indicate a current or past HSV infection.

0050379 Herpes Simplex Virus Type 1 Glycoprotein G-Specific Antibody, IgG by ELISA, CSF
0.89 IV or less Negative - No significant level of detectable IgG antibody to HSV type 1 glycoprotein G.
0.90-1.10 IV Equivocal - Questionable presence of IgG antibody to HSV type 1.  Repeat testing in 10-14 days may be helpful.
1.11 IV or greater Positive - IgG antibody to HSV type 1 glycoprotein G detected, which may indicate a current or past infection.

0050359 Herpes Simplex Virus Type 2 Glycoprotein G-Specific Antibody, IgG by ELISA, CSF
0.89 IV or less Negative - No significant level of detectable IgG antibody to HSV type 2 glycoprotein G.
0.90-1.10 IV Equivocal - Questionable presence of IgG antibody to HSV type 2.  Repeat testing in 10-14 days may be helpful.
1.11 IV or greater Positive - IgG antibody to HSV type 2 glycoprotein G detected, which may indicate a current or past HSV infection.

0050238 West Nile Virus Antibody, IgG by ELISA, CSF
1.29 IV or less Negative - No significant level of West Nile virus IgG antibody detected.
1.30-1.49 IV Equivocal - Questionable presence of West Nile virus IgG antibody detected.  Repeat testing in 10-14 days may be helpful.
1.50 IV or greater Positive - Presence of IgG antibody to West Nile virus detected, suggestive of current or past infection.

0050239 West Nile Virus Antibody, IgM by ELISA, CSF
0.89 IV or less Negative - No significant level of West Nile virus IgM antibody detected.
0.90-1.10 IV Equivocal - Questionable presence of West Nile virus IgM antibody detected.  Repeat testing in 10-14 days may be helpful.
1.11 IV or greater Positive - Presence of IgM antibody to West Nile virus detected, suggestive of current or recent infection.

Interpretive Data



Compliance Statement B: For laboratory developed tests not using a RUO kit, and for FDA approved, cleared or 510(k) exempt assays with alterations. This test was developed and its performance characteristics determined by ARUP Laboratories. The U. S. Food and Drug Administration has not approved or cleared this test; however, FDA clearance or approval is not currently required for clinical use. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions.

Note

If HSV 1 and/or 2 IgG, CSF is 1.10 IV or greater, then HSV 1 G-Specific IgG, CSF and HSV 2 G-Specific IgG, CSF will be added. Additional charges apply.

Hotline History
N/A
CPT Codes

86765 x2; 86735 x2; 86787 x2; 86789; 86788; 86694 x2; if reflexed, add 86695; 86696

Components
Component Test Code* Component Chart Name LOINC
0050238 West Nile Virus Antibody IgG CSF 39572-3
0050239 West Nile Virus Antibody IgM CSF 39573-1
0050394 HSV 1/2 Antibody Screen IgG, CSF 13249-8
0050408 HSV 1 and/or 2 Antibodies IgM, CSF 63432-9
0054440 Measles, Rubeola, Antibody IgG CSF 9566-1
0054441 Measles, Rubeola, Antibody IgM CSF 13283-7
0054442 Mumps Virus Antibody IgG CSF 13266-2
0054443 Mumps Virus Antibody IgM CSF 13267-0
0054444 VZV Antibody IgG CSF 58755-0
0054445 VZV Antibody IgM CSF 31695-0
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.
Aliases
Encephalitis Panel with Reflex to Herpes Simplex Virus Types 1 and 2 Glycoprotein G-Specific Antibodies, IgG, CSF